Journal: Diagnostic Microbiology and Infectious Disease

Article Title: Enhanced Detection of Community-Acquired Pneumonia Pathogens With the BioFire® Pneumonia FilmArray® Panel

doi: 10.1016/j.diagmicrobio.2020.115246

Figure Lengend Snippet: Components of Multi-Test Bundle and BioFire® Pneumonia FilmArray® Testing

Article Snippet: The Biofire® Pneumonia FilmArray® (BPFA) panel probes sputum samples for 8 respiratory viruses and 18 bacteria with a 1 to 2-hour TAT.

Techniques:

Journal: Diagnostic Microbiology and Infectious Disease

Article Title: Enhanced Detection of Community-Acquired Pneumonia Pathogens With the BioFire® Pneumonia FilmArray® Panel

doi: 10.1016/j.diagmicrobio.2020.115246

Figure Lengend Snippet: Comparison of organism targets in the Biofire® Respiratory FilmArray and the Biofire Pneumonia FilmArray® Panels. The Respiratory Panel requires a nasopharyngeal swab and the Pneumonia Panel requires sputum * .

Article Snippet: The Biofire® Pneumonia FilmArray® (BPFA) panel probes sputum samples for 8 respiratory viruses and 18 bacteria with a 1 to 2-hour TAT.

Techniques: Comparison, Bacteria, Virus

Journal: Diagnostic Microbiology and Infectious Disease

Article Title: Enhanced Detection of Community-Acquired Pneumonia Pathogens With the BioFire® Pneumonia FilmArray® Panel

doi: 10.1016/j.diagmicrobio.2020.115246

Figure Lengend Snippet: Clinical Classification of Patients Based on Integration of Test Results with Clinical Judgment

Article Snippet: The Biofire® Pneumonia FilmArray® (BPFA) panel probes sputum samples for 8 respiratory viruses and 18 bacteria with a 1 to 2-hour TAT.

Techniques: Imaging, Biomarker Discovery, Virus

Journal: Diagnostic Microbiology and Infectious Disease

Article Title: Enhanced Detection of Community-Acquired Pneumonia Pathogens With the BioFire® Pneumonia FilmArray® Panel

doi: 10.1016/j.diagmicrobio.2020.115246

Figure Lengend Snippet: Number of patients with bacterial, viral, or any (bacterial and/or viral) potential pathogens detected by MTB and BPFA

Article Snippet: The Biofire® Pneumonia FilmArray® (BPFA) panel probes sputum samples for 8 respiratory viruses and 18 bacteria with a 1 to 2-hour TAT.

Techniques: Bacteria, Virus

Journal: Diagnostic Microbiology and Infectious Disease

Article Title: Enhanced Detection of Community-Acquired Pneumonia Pathogens With the BioFire® Pneumonia FilmArray® Panel

doi: 10.1016/j.diagmicrobio.2020.115246

Figure Lengend Snippet: Comparison of MTB versus BPFA for detecting number of patients with potential bacterial pathogens, with or without detectable virus. Some patients were detected with more than one bacterial species.

Article Snippet: The Biofire® Pneumonia FilmArray® (BPFA) panel probes sputum samples for 8 respiratory viruses and 18 bacteria with a 1 to 2-hour TAT.

Techniques: Comparison, Virus

Journal: Diagnostic Microbiology and Infectious Disease

Article Title: Enhanced Detection of Community-Acquired Pneumonia Pathogens With the BioFire® Pneumonia FilmArray® Panel

doi: 10.1016/j.diagmicrobio.2020.115246

Figure Lengend Snippet: Comparison of number of patients detected with Streptococcus pneumoniae by individual elements of the multi-test bundle vs the BioFire® Pneumonia FilmArray®. Some patients had more than one test element positive for S. pneumoniae . PCR denotes polymerase chain reaction.

Article Snippet: The Biofire® Pneumonia FilmArray® (BPFA) panel probes sputum samples for 8 respiratory viruses and 18 bacteria with a 1 to 2-hour TAT.

Techniques: Comparison, Polymerase Chain Reaction

Journal: Diagnostic Microbiology and Infectious Disease

Article Title: Enhanced Detection of Community-Acquired Pneumonia Pathogens With the BioFire® Pneumonia FilmArray® Panel

doi: 10.1016/j.diagmicrobio.2020.115246

Figure Lengend Snippet: Comparison of MTB versus BPFA for detecting number of patients with potential viral pathogens, with or without detectable bacteria Some patients were detected with more than one viral species.

Article Snippet: The Biofire® Pneumonia FilmArray® (BPFA) panel probes sputum samples for 8 respiratory viruses and 18 bacteria with a 1 to 2-hour TAT.

Techniques: Comparison, Bacteria

Journal: Diagnostic Microbiology and Infectious Disease

Article Title: Enhanced Detection of Community-Acquired Pneumonia Pathogens With the BioFire® Pneumonia FilmArray® Panel

doi: 10.1016/j.diagmicrobio.2020.115246

Figure Lengend Snippet: Comparative detection of multiple bacterial and viral species with BPFA versus MTB

Article Snippet: The Biofire® Pneumonia FilmArray® (BPFA) panel probes sputum samples for 8 respiratory viruses and 18 bacteria with a 1 to 2-hour TAT.

Techniques: Virus, Bacteria

Journal: Diagnostic Microbiology and Infectious Disease

Article Title: Enhanced Detection of Community-Acquired Pneumonia Pathogens With the BioFire® Pneumonia FilmArray® Panel

doi: 10.1016/j.diagmicrobio.2020.115246

Figure Lengend Snippet: Comparative laboratory cost of MTB vs projected cost of BPFA bundle

Article Snippet: The Biofire® Pneumonia FilmArray® (BPFA) panel probes sputum samples for 8 respiratory viruses and 18 bacteria with a 1 to 2-hour TAT.

Techniques:

Journal: Critical Care

Article Title: Multicenter evaluation of a syndromic rapid multiplex PCR test for early adaptation of antimicrobial therapy in adult patients with pneumonia

doi: 10.1186/s13054-020-03114-y

Figure Lengend Snippet: Pathogens targeted by the BioFire® FilmArray® Pneumonia Panel

Article Snippet: The BioFire® FilmArray® Pneumonia Panel (bioMerieux S.A., Marcy-l’Etoile, France) is a novel assay able to simultaneously identify 27 of the most common pathogens involved in lower respiratory tract infections (semi-quantitative results for 11 Gram-negative and 4 Gram-positive bacteria, qualitative results for 3 atypical bacteria and 9 viruses) as well as 7 antibiotic resistance genes (Fig. ).

Techniques:

Journal: Journal of Clinical Microbiology

Article Title: Evaluation of Commercial Molecular Diagnostic Methods for Detection and Determination of Macrolide Resistance in Mycoplasma pneumoniae

doi: 10.1128/JCM.00242-20

Figure Lengend Snippet: Comparative features of six commercial molecularly based tests to detect M. pneumoniae d

Article Snippet: We evaluated six commercial molecular tests targeting Mycoplasma pneumoniae , namely, the BioFire FilmArray respiratory panel (RP), the Meridian Alethia Mycoplasma Direct, the GenMark ePlex respiratory pathogen panel (RPP), the Luminex NxTAG RPP, the ELITech ELITe InGenius Mycoplasma MGB research use only (RUO) PCR, and the SpeeDx Resistance Plus MP assays.

Techniques: Luminex

Journal: Journal of Clinical Microbiology

Article Title: Evaluation of Commercial Molecular Diagnostic Methods for Detection and Determination of Macrolide Resistance in Mycoplasma pneumoniae

doi: 10.1128/JCM.00242-20

Figure Lengend Snippet: Commercial molecular diagnostic test performance characteristics for the detection of M. pneumoniae a

Article Snippet: We evaluated six commercial molecular tests targeting Mycoplasma pneumoniae , namely, the BioFire FilmArray respiratory panel (RP), the Meridian Alethia Mycoplasma Direct, the GenMark ePlex respiratory pathogen panel (RPP), the Luminex NxTAG RPP, the ELITech ELITe InGenius Mycoplasma MGB research use only (RUO) PCR, and the SpeeDx Resistance Plus MP assays.

Techniques: Diagnostic Assay

Journal: Microbiology Spectrum

Article Title: Diagnosis and Treatment of Bacterial Pneumonia in Critically Ill Patients with COVID-19 Using a Multiplex PCR Assay: A Large Italian Hospital’s Five-Month Experience

doi: 10.1128/Spectrum.00695-21

Figure Lengend Snippet: Comparison between the FilmArray pneumonia plus panel and standard-of-care reference testing results for LRT samples from COVID-19 patients with bacterial pneumonia ^a

Article Snippet: In September 2020, when the second wave of the SARS-CoV-2 pandemic was raging in Italy, we implemented the multiplexed, semiquantitative FilmArray pneumonia plus (FA-PP) panel (BioFire, Salt Lake City, UT, USA) assay ( ) for routine clinical use at our institution (a large Italian university hospital).

Techniques: Comparison

Journal: Microbiology Spectrum

Article Title: Diagnosis and Treatment of Bacterial Pneumonia in Critically Ill Patients with COVID-19 Using a Multiplex PCR Assay: A Large Italian Hospital’s Five-Month Experience

doi: 10.1128/Spectrum.00695-21

Figure Lengend Snippet: Quantitative result agreement between the FilmArray pneumonia plus (FA-PP) panel and standard-of-care (SoC) culture testing methods for 202 bacterial organisms detected in bronchoalveolar lavage (BAL) fluid or endotracheal aspirate (ETA) samples from ICU patients. All but 22 (which did not grow in culture) organisms were detected at or above the 1 × 10 4 CFU/ml (BAL fluid sample) or 1 × 10 5 CFU/ml (ETA sample) thresholds for clinically relevant quantification by both methods. The diagonal dashed line connects dots that represent bacterial organisms with fully concordant results (71/202; 35.1%), whereas dots above or below the line represent bacterial organisms with SoC culture loads that exceeded (18/202, 8.9%) or did not exceed (113/202, 56.0%), respectively, those of the FA-PP panel by ≥1 log 10 . Shades of gray are used to depict the different numbers of samples corresponding to each dot.

Article Snippet: In September 2020, when the second wave of the SARS-CoV-2 pandemic was raging in Italy, we implemented the multiplexed, semiquantitative FilmArray pneumonia plus (FA-PP) panel (BioFire, Salt Lake City, UT, USA) assay ( ) for routine clinical use at our institution (a large Italian university hospital).

Techniques:

Journal: Microbiology Spectrum

Article Title: Diagnosis and Treatment of Bacterial Pneumonia in Critically Ill Patients with COVID-19 Using a Multiplex PCR Assay: A Large Italian Hospital’s Five-Month Experience

doi: 10.1128/Spectrum.00695-21

Figure Lengend Snippet: Overview of antimicrobial therapy interventions performed according to FilmArray pneumonia plus (FA-PP) panel results. Interventions were stratified into three relevant groups based on the full concordance of positive (A) or negative (B) FA-PP testing results or the partial or full discordance (C) of FA-PP testing results, respectively, with the results by standard-of-care (SoC) culture for the lower respiratory tract (LRT) samples tested. For each LRT sample, the type(s) of interventions and the antibiotics involved (one or more per intervention) are reported, together with whether the interventions resulted in appropriate antimicrobial escalations/initiations (93 in panel A and 22 in panel C) or deescalations (10 in panel A and 6 in panel C), appropriate antimicrobial discontinuations (5 in panel B), and inappropriate antimicrobial escalations/initiations (4 in panel C). Cases with no antimicrobial therapy interventions (5 in panel A, 85 in panel B, and 4 in panel C) are reported as well.

Article Snippet: In September 2020, when the second wave of the SARS-CoV-2 pandemic was raging in Italy, we implemented the multiplexed, semiquantitative FilmArray pneumonia plus (FA-PP) panel (BioFire, Salt Lake City, UT, USA) assay ( ) for routine clinical use at our institution (a large Italian university hospital).

Techniques:

Journal: Microbiology Spectrum

Article Title: Diagnosis and Treatment of Bacterial Pneumonia in Critically Ill Patients with COVID-19 Using a Multiplex PCR Assay: A Large Italian Hospital’s Five-Month Experience

doi: 10.1128/Spectrum.00695-21

Figure Lengend Snippet: Characteristics of bacterial pneumonia episodes detected or not detected by the FilmArray pneumonia plus panel in 97 mechanically ventilated patients with COVID-19 ^a

Article Snippet: In September 2020, when the second wave of the SARS-CoV-2 pandemic was raging in Italy, we implemented the multiplexed, semiquantitative FilmArray pneumonia plus (FA-PP) panel (BioFire, Salt Lake City, UT, USA) assay ( ) for routine clinical use at our institution (a large Italian university hospital).

Techniques: